InMed Pharmaceuticals (INM) Income towards Parent Company (2021 - 2026)
InMed Pharmaceuticals (INM) posted quarterly Income towards Parent Company of -$174585.0 for Q1 2026, down 224.14% year-over-year from $140635.7 in Q1 2025, and up 91.39% quarter-over-quarter from -$2.0 million in Q4 2025.
InMed Pharmaceuticals (INM) Income towards Parent Company (2021 - 2026) Analysis & Trends
InMed Pharmaceuticals' Income towards Parent Company history runs 6 years deep, the most recent figure standing at -$174585.0 for Q1 2026.
- In Q1 2026, Income towards Parent Company fell 224.14% year-over-year to -$174585.0; the TTM figure through Mar 2026 stood at -$5.2 million (up 16.05% YoY), while the FY2025 annual figure was -$8.2 million, down 6.34% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$174585.0, up from -$2.0 million in the prior quarter.
- The five-year high for Income towards Parent Company was -$53861.0 in Q1 2025, with the low at -$7.9 million in Q2 2022.
- The 5-year median for Income towards Parent Company is -$1.9 million (2024), against an average of -$2.1 million.
- The sharpest annual moves came in 2024 and 2025: Income towards Parent Company slumped 473.57% in 2024, then jumped 96.87% in 2025.
- InMed Pharmaceuticals' Income towards Parent Company stood at -$2.1 million in 2022, then advanced by 29.55% to -$1.5 million in 2023, then slumped by 74.2% to -$2.6 million in 2024, then advanced by 21.23% to -$2.0 million in 2025, then soared by 91.39% to -$174585.0 in 2026.
- Business Quant data shows INM's Income towards Parent Company at -$174585.0 in Q1 2026, -$2.0 million in Q4 2025, and -$1.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | InMed Pharmaceuticals | 6.38 Mn | 1.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -174,585.00 |
| Dec 31, 2025 | -2.03 Mn |
| Sep 30, 2025 | -1.73 Mn |
| Jun 30, 2025 | -1.31 Mn |
| Mar 31, 2025 | -53,861.00 |
| Dec 31, 2024 | -2.58 Mn |
| Sep 30, 2024 | -1.68 Mn |
| Jun 30, 2024 | -1.93 Mn |
| Mar 31, 2024 | -1.72 Mn |
| Dec 31, 2023 | -1.48 Mn |
| Sep 30, 2023 | -2.54 Mn |
| Jun 30, 2023 | -336,591.00 |
| Mar 31, 2023 | -2.00 Mn |
| Dec 31, 2022 | -2.10 Mn |
| Sep 30, 2022 | -3.51 Mn |
| Jun 30, 2022 | -7.87 Mn |
| Mar 31, 2022 | -3.48 Mn |
| Dec 31, 2021 | -4.28 Mn |
| Sep 30, 2021 | -2.97 Mn |